Author

Rashmi Shivakumar

Observed name: Rashmi Sivakumar

Institution: University of Mysore

Observed institution: University of Mysore

ORCID: 0009-0007-1932-6149

Observed ORCID: 0009-0007-1932-6149

OpenAlex ID: A5038754040

Development of 1-(4-substitutedpiperazin-1-yl)-2-(2,4-methoxybenzylthio) Pyrimidin-4-yloxyethanones That Target Poly Adp-ribose Polymerase in Human Breast Cancer Cells.

2022 · Suresha N. Deveshegowda, Prashant K. Metri, et al. · Molecules · 17

De Novo Design of Imidazopyridine-Tethered Pyrazolines That Target Phosphorylation of STAT3 in Human Breast Cancer Cells

2023 · Akshay Ravish, Rashmi Shivakumar, et al. · Bioengineering · 14

Development of Novel Indazolyl‐Acyl Hydrazones as Antioxidant and Anticancer Agents that Target VEGFR‐2 in Human Breast Cancer Cells

2024 · Sindhu M. Parameshwaraiah, Rashmi Shivakumar, et al. · Chemistry & Biodiversity · 10

Discovery of Piperazin‐2‐yl‐pyrimidines as Anticancer Agents via Targeting JNK Signaling Pathway in Human MCF‐7 Breast Carcinoma

2024 · Rashmi Shivakumar, Gautam Sethi, et al. · ChemistrySelect · 2

Pyrimidine-Piperazine Hybrids as Potential PARP1 Inhibitors: Dual in silico and in vitro Approaches against Breast Cancer

2026 · Rashmi Shivakumar, Narasimha M. Beeraka, et al. · Asian Journal of Chemistry

Pyrazoline–Imidazopyridine Hybrids as Beclin‐1 Mimetics Driving Dual Apoptotic and Autophagy in Breast Cancer

2026 · Rashmi Shivakumar, Narasimha M. Beeraka, et al. · Chemical Biology & Drug Design

Nano-TiO2 Catalyst-Based Method Development to Synthesize Pyrano-Chromenes Targeting TFF3 in Breast Cancer

2026 · Dukanya Dukanya, Rashmi Sivakumar, et al. · Figshare

Nano-TiO 2 Catalyst-Based Method Development to Synthesize Pyrano-Chromenes Targeting TFF3 in Breast Cancer

2026 · Dukanya Dukanya, Rashmi Sivakumar, et al. · Polycyclic aromatic compounds

Development of novel pyridine containing acylhydrazones as anticancer agents that target VEGFR-2 in human breast cancer cells

2025 · Rashmi Shivakumar, Bhoomika B. Ravi, et al. · Letters in Drug Design & Discovery

Works count: 9

Citation count: 43

H-index: 3

I10-index: 3